• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

游离脂肪酸受体4(FFAR4)的抗动脉粥样硬化潜力

Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4).

作者信息

Kiepura Anna, Stachyra Kamila, Olszanecki Rafał

机构信息

Chair of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, 31-531 Krakow, Poland.

出版信息

Biomedicines. 2021 Apr 24;9(5):467. doi: 10.3390/biomedicines9050467.

DOI:10.3390/biomedicines9050467
PMID:33923318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8146529/
Abstract

Fatty acids (FAs) are considered not only as a basic nutrient, but are also recognized as signaling molecules acting on various types of receptors. The receptors activated by FAs include the family of rhodopsin-like receptors: GPR40 (FFAR1), GPR41 (FFAR3), GPR43 (FFAR2), GPR120 (FFAR4), and several other, less characterized G-protein coupled receptors (GPR84, GPR109A, GPR170, GPR31, GPR132, GPR119, and Olfr78). The ubiquitously distributed FFAR4 can be activated by saturated and unsaturated medium- and long-chain fatty acids (MCFAs and LCFAs), as well as by several synthetic agonists (e.g., TUG-891). The stimulation of FFAR4 using selective synthetic agonists proved to be promising strategy of reduction of inflammatory reactions in various tissues. In this paper, we summarize the evidence showing the mechanisms of the potential beneficial effects of FFAR4 stimulation in atherosclerosis. Based partly on our own results, we also suggest that an important mechanism of such activity may be the modulatory influence of FFAR4 on the phenotype of macrophage involved in atherogenesis.

摘要

脂肪酸(FAs)不仅被视为一种基本营养素,还被公认为作用于各种类型受体的信号分子。被脂肪酸激活的受体包括视紫红质样受体家族:GPR40(FFAR1)、GPR41(FFAR3)、GPR43(FFAR2)、GPR120(FFAR4),以及其他几种特性较少的G蛋白偶联受体(GPR84、GPR109A、GPR170、GPR31、GPR132、GPR119和Olfr78)。广泛分布的FFAR4可被饱和和不饱和中链及长链脂肪酸(MCFAs和LCFAs)以及几种合成激动剂(如TUG - 891)激活。使用选择性合成激动剂刺激FFAR4被证明是减少各种组织中炎症反应的一种有前景的策略。在本文中,我们总结了显示FFAR4刺激在动脉粥样硬化中潜在有益作用机制的证据。部分基于我们自己的结果,我们还提出这种活性的一个重要机制可能是FFAR4对参与动脉粥样硬化形成的巨噬细胞表型的调节作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/408e/8146529/dae1b3bf5f28/biomedicines-09-00467-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/408e/8146529/2c7118a1e5ae/biomedicines-09-00467-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/408e/8146529/dae1b3bf5f28/biomedicines-09-00467-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/408e/8146529/2c7118a1e5ae/biomedicines-09-00467-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/408e/8146529/dae1b3bf5f28/biomedicines-09-00467-g002.jpg

相似文献

1
Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4).游离脂肪酸受体4(FFAR4)的抗动脉粥样硬化潜力
Biomedicines. 2021 Apr 24;9(5):467. doi: 10.3390/biomedicines9050467.
2
The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE-Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype.FFAR4 激动剂 TUG-891 在载脂蛋白 E 敲除小鼠中的抗动脉粥样硬化作用与巨噬细胞向 M2 表型极化增加有关。
Int J Mol Sci. 2021 Sep 9;22(18):9772. doi: 10.3390/ijms22189772.
3
Free fatty acid receptors as therapeutic targets for the treatment of diabetes.游离脂肪酸受体作为糖尿病治疗的靶点
Front Pharmacol. 2014 Nov 6;5:236. doi: 10.3389/fphar.2014.00236. eCollection 2014.
4
Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease.游离脂肪酸受体作为肝脏疾病的介质和治疗靶点
Front Physiol. 2021 Apr 7;12:656441. doi: 10.3389/fphys.2021.656441. eCollection 2021.
5
Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.靶向游离脂肪酸受体 1 治疗卵巢癌:限制脂肪细胞-卵巢癌细胞依赖的新策略。
Gynecol Oncol. 2016 Apr;141(1):72-9. doi: 10.1016/j.ygyno.2016.02.026.
6
Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice.GW9508 - 游离脂肪酸受体激活剂 - 在载脂蛋白 E 基因敲除小鼠中的抗动脉粥样硬化作用。
Pharmacol Rep. 2019 Aug;71(4):551-555. doi: 10.1016/j.pharep.2019.02.014. Epub 2019 Feb 21.
7
Free Fatty Acid Receptors in Health and Disease.游离脂肪酸受体在健康与疾病中的作用
Physiol Rev. 2020 Jan 1;100(1):171-210. doi: 10.1152/physrev.00041.2018. Epub 2019 Sep 5.
8
The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.FFAR4 激动剂 TUG-891 对载脂蛋白 E 基因敲除小鼠肝脂肪变性的影响。
Cardiovasc Drugs Ther. 2024 Aug;38(4):667-678. doi: 10.1007/s10557-023-07430-7. Epub 2023 Jan 27.
9
Novel identification of the free fatty acid receptor FFAR1 that promotes contraction in airway smooth muscle.促进气道平滑肌收缩的游离脂肪酸受体FFAR1的新发现。
Am J Physiol Lung Cell Mol Physiol. 2015 Nov 1;309(9):L970-82. doi: 10.1152/ajplung.00041.2015. Epub 2015 Sep 4.
10
Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook.游离脂肪酸受体(FFARs)在脂肪组织中的作用:生理作用和治疗前景。
Cells. 2022 Feb 21;11(4):750. doi: 10.3390/cells11040750.

引用本文的文献

1
Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.非酒精性脂肪性肝病的药物治疗:当代治疗方法与未来展望
Int J Mol Sci. 2025 Jul 7;26(13):6518. doi: 10.3390/ijms26136518.
2
FFAR4 Deficiency Increases Necrotic Cores in Advanced Lesions of ApoE Mice-Brief Report.FFAR4基因缺陷增加载脂蛋白E基因敲除小鼠晚期病变中的坏死核心——简要报告
Arterioscler Thromb Vasc Biol. 2025 May;45(5):675-682. doi: 10.1161/ATVBAHA.124.322371. Epub 2025 Mar 6.
3
Effect of plasma free fatty acids on lung function in male COPD patients.

本文引用的文献

1
Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators.游离脂肪酸受体及其别构调节剂的药理学。
Int J Mol Sci. 2021 Feb 10;22(4):1763. doi: 10.3390/ijms22041763.
2
Development of Free Fatty Acid Receptor 4 (FFA4/GPR120) Agonists in Health Science.健康科学领域中游离脂肪酸受体4(FFA4/GPR120)激动剂的研发
Biomol Ther (Seoul). 2021 Jan 1;29(1):22-30. doi: 10.4062/biomolther.2020.213.
3
NAFLD and cardiovascular diseases: a clinical review.非酒精性脂肪性肝病与心血管疾病:临床综述。
血浆游离脂肪酸对男性慢性阻塞性肺疾病患者肺功能的影响。
Sci Rep. 2025 Jan 27;15(1):3377. doi: 10.1038/s41598-025-86628-1.
4
Free Fatty Acids and Free Fatty Acid Receptors: Role in Regulating Arterial Function.游离脂肪酸和游离脂肪酸受体:在调节动脉功能中的作用。
Int J Mol Sci. 2024 Jul 18;25(14):7853. doi: 10.3390/ijms25147853.
5
G Protein-Coupled Receptor 40 Agonist LY2922470 Alleviates Ischemic-Stroke-Induced Acute Brain Injury and Functional Alterations in Mice.G 蛋白偶联受体 40 激动剂 LY2922470 减轻小鼠缺血性脑卒中引起的急性脑损伤和功能改变。
Int J Mol Sci. 2023 Jul 31;24(15):12244. doi: 10.3390/ijms241512244.
6
Medium-chain fatty acids modify macrophage expression of metabolic and inflammatory genes in a PPAR β/δ-dependent manner.中链脂肪酸以 PPARβ/δ 依赖的方式修饰巨噬细胞代谢和炎症基因的表达。
Sci Rep. 2023 Jul 18;13(1):11573. doi: 10.1038/s41598-023-38700-x.
7
Lipid-Sensing Receptor FFAR4 Modulates Pulmonary Epithelial Homeostasis following Immunogenic Exposures Independently of the FFAR4 Ligand Docosahexaenoic Acid (DHA).脂感应受体 FFAR4 可调节免疫原性暴露后肺上皮细胞的稳态,而不依赖 FFAR4 配体二十二碳六烯酸(DHA)。
Int J Mol Sci. 2023 Apr 11;24(8):7072. doi: 10.3390/ijms24087072.
8
The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.FFAR4 激动剂 TUG-891 对载脂蛋白 E 基因敲除小鼠肝脂肪变性的影响。
Cardiovasc Drugs Ther. 2024 Aug;38(4):667-678. doi: 10.1007/s10557-023-07430-7. Epub 2023 Jan 27.
9
Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients.ω-3 脂肪酸可协调糖尿病患者的糖和脂代谢。
Lipids Health Dis. 2022 Mar 25;21(1):31. doi: 10.1186/s12944-022-01642-w.
10
Transcriptomic Analysis Identifies Differentially Expressed Genes Associated with Vascular Cuffing and Chronic Inflammation Mediating Early Thrombosis in Arteriovenous Fistula.转录组学分析鉴定出与动静脉内瘘血管套叠及介导早期血栓形成的慢性炎症相关的差异表达基因。
Biomedicines. 2022 Feb 13;10(2):433. doi: 10.3390/biomedicines10020433.
Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7. Epub 2020 Jul 21.
4
Free Fatty Acid Receptors 2 and 3 as Microbial Metabolite Sensors to Shape Host Health: Pharmacophysiological View.游离脂肪酸受体2和3作为塑造宿主健康的微生物代谢产物传感器:药物生理学视角
Biomedicines. 2020 Jun 8;8(6):154. doi: 10.3390/biomedicines8060154.
5
G-Protein-Coupled Receptors 120 Agonist III Improves Hepatic Inflammation and ER Stress in Steatohepatitis.G蛋白偶联受体120激动剂III改善脂肪性肝炎中的肝脏炎症和内质网应激。
Dig Dis Sci. 2021 Apr;66(4):1090-1096. doi: 10.1007/s10620-020-06280-9. Epub 2020 May 5.
6
Agonism of GPR120 prevents ox-LDL-induced attachment of monocytes to endothelial cells.激动 GPR120 可防止 ox-LDL 诱导的单核细胞附着在内皮细胞上。
Chem Biol Interact. 2020 Jan 25;316:108916. doi: 10.1016/j.cbi.2019.108916. Epub 2019 Dec 21.
7
Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases.游离脂肪酸受体作为炎症性肠病新的潜在治疗靶点。
Pharmacol Res. 2020 Feb;152:104604. doi: 10.1016/j.phrs.2019.104604. Epub 2019 Dec 14.
8
Free Fatty Acid Receptors in Health and Disease.游离脂肪酸受体在健康与疾病中的作用
Physiol Rev. 2020 Jan 1;100(1):171-210. doi: 10.1152/physrev.00041.2018. Epub 2019 Sep 5.
9
Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice.GW9508 - 游离脂肪酸受体激活剂 - 在载脂蛋白 E 基因敲除小鼠中的抗动脉粥样硬化作用。
Pharmacol Rep. 2019 Aug;71(4):551-555. doi: 10.1016/j.pharep.2019.02.014. Epub 2019 Feb 21.
10
Marine and plant-based -3 PUFA and atherosclerotic cardiovascular disease.海洋和植物源 -3PUFA 与动脉粥样硬化性心血管疾病。
Proc Nutr Soc. 2020 Feb;79(1):22-29. doi: 10.1017/S0029665119000582. Epub 2019 Apr 15.